Record quarter, but ₹3,000-Crore capex repricing shifts focus to execution
Laurus Labs delivered its highest-ever quarter (₹2,206 Cr revenue, +33% YoY; ₹436 Cr PAT, +124% YoY) and beat its own guidance on margins. But the company also raised capex by 50% and flagged Q3 softness — reframing the quarter from a runaway growth story into a capex-intensity test.
₹2,206 Cr
+33.4% YoY, +8.9% QoQ
₹436 Cr
+124.3% YoY, NPM 19.6%
34.5%
+270 bps YoY, guidance 30%+
₹3,000 Cr
FY27–'28 (raised from ₹2,000 Cr)
Laurus Labs hit a quarter that looks like an inflection. The highest revenue and profit in its history, margin expansion to 34.5%, and CDMO growth at 86% YoY all validate the long-term CDMO thesis. But the same call that announced these numbers also raised capex by ₹1,000 Cr and disclosed that Q3 will be "soft." The quarter's real story is not the headline — it's what management is now betting.
Where the quarter's profit came from
The PAT story is entirely organic. CDMO revenue jumped 86% to ₹875 Cr (H1 ₹1,710 Cr, +77% YoY) on 125 active programs, with pricing power evident in the 34.5% EBITDA margin — a 270-basis-point YoY jump. Affordable Medicines (ARV APIs, finished drugs) grew 15% to ₹1,302 Cr, steady pricing despite supply-chain volatility. Laurus Bio, the fermentation-platform subsidiary, fell 16% to ₹29 Cr, down 68% on a half-year basis from prior-year ₹64 Cr due to campaign phasing and facility validation work. The $4 billion-plus CDMO market tailwind is real. The issue is not growth — it's what expansion now costs.
Q2 total revenue ₹2,206 Cr, highest ever
Delivered ₹2,206.4 Cr; YoY +33.4%, QoQ +8.9%
Supported
CDMO 86% growth with 125 active programs
Q2 ₹875 Cr at +86% YoY; H1 ₹1,710 Cr at +77% YoY; program diversity confirmed
Supported
Gross margin 63%, EBITDA margin 34.5%
Delivered Q2 OPM 34%, consistent with margin expansion from Q1
Supported
Capex raised to ₹3,000 Cr (from ₹2,000 Cr) for FY27–'28
H1 capex ₹864 Cr on track; guidance raised, aligns with peptide/Laurus Bio expansion timeline
Supported (but forward-loading risk)
50% CDMO revenue by FY30 and ROCE toward 25%
Current CDMO ~35–40% of revenue; ROCE 22.5% H1 vs. 17.7% FY26; trajectory plausible over 4 years
Plausible but unquantified (no FY28–29 interim milestones given)
Peptide large-block commercial revenue starting '28
Validation 12–18 months, facility commissioned for validation batches; no ramp profile or ₹875M+ capex ROI disclosed
Partially answered (vague on revenue inflection timing post-validation)
What changed on this call
Capex raised ₹1,000 Cr to ₹3,000 Cr (FY27–'28) — accelerating peptide, Laurus Bio, KRKA JV expansion
CDMO growth outpacing: 86% in Q2 (prior implied ~40–50%)
ROCE trajectory ahead: 22.5% (H1) vs. prior FY26 17.7%; on track to 25% target
Q3 flagged as "soft" due to Laurus Bio validation and campaign phasing — no guidance for H2 given
Margin guidance sustained at 30%+ EBITDA floor; achieved 34.5% in Q2 despite R&D spending +34% YoY
Street positioning: price action, ownership, and the overbought signal
At ₹2,348 (as of November 2), Laurus is trading 3.73% below its all-time high, up 155.79% from its 52-week low, with RSI at 71.8 — in overbought territory. The stock is trading above its 20-, 50-, and 200-day simple moving averages, signaling strong uptrend momentum. But the recent bulk-deal activity tells a different story. Foreign institutional investors (FIIs) have increased their stake to 28.00% (up 218 basis points quarter-on-quarter), but the most recent block trades show BNP Paribas and Société Générale selling ₹62–₹51 lakh shares at ₹1,914–₹1,903, just 1–2% below current levels — classic late-riser selling into strength. Integrated Core Strategies (Asia) also appears on the block list as both buyer and seller, likely a rebalance. The overbought RSI combined with FII trimming near the highs is a credibility test: the market has priced in the record quarter and the CDMO growth story. What it has NOT priced in is whether management can deliver peptide revenue in '28 and generate acceptable returns on the ₹3,000 Cr capex bet without stretching the balance sheet.
The debate
Bull: Record quarter proves CDMO is real and durable (not a blip). Margin expansion (34.5% EBITDA) shows pricing power. ROCE uplift (17.7% → 22.5%) vindicates the capex thesis. Peptide pipeline and Laurus Bio IP are monopoly-like moats; once validations pass (12–18 months), the capex becomes cheap. FY30 50% CDMO target is credible given current trajectory. Bear: The capex raise is a statement of risk, not confidence. Q3 flagged soft. Peptide timeline is vague; no FY28–29 revenue run-rate disclosed. Laurus Bio down 68% YoY and still not ramping — why should we trust facility validation will stick? At RSI 71.8, upside is already priced in. The next two quarters will be about execution, not growth beats. Honest read: Laurus is a high-quality compounder with genuine CDMO momentum and two multi-year optionality bets (peptide, Laurus Bio). The reported quarter is organic, margins are expanding, and ROCE is improving. But the capex repricing and Q3 softness are management's way of saying: "We are now in a capex cycle, not a cash generation cycle." The street has priced in the CDMO story; it has not priced in capex intensity. Hold at ₹2,348 is the honest call — the stock is expensive, execution is now binary, and upside is gated on Q3 and Q4 validation batches.
Ranked risks (how much they should concern a holder)
1
HighPeptide validation delays or regulatory setbacks (12–18 month timeline extends beyond '28)
Peptide is the ₹800–1,000 Cr capex centerpiece. A 12–24 month delay in commercial revenue would push ROI to FY30, straining FCF during a ₹3,000 Cr spend cycle. No interim FY28–29 numbers disclosed; a miss would undercut the entire capex narrative.
2
HighCapex-driven FCF pressure (₹3,000 Cr over 24 months vs. current ~₹1,500 Cr annual capex run)
At current EBITDA run-rate (~₹3,000 Cr annual), net capex of ₹3,000 Cr (gross minus ₹500–800 Cr annual divestments/exit) will consume most of OCF for 2 years. Debt-to-EBITDA rises to 1.5–1.8x. Refinancing risk is low, but dividend/buyback flexibility is gone.
3
HighLaurus Bio ramp failure or repeated validation delays (down 68% YoY, core to long-term strategy)
Laurus Bio is the fermentation platform; Phase 1 facility (500K liters) is supposed to be operational by end FY27. Yield issues, regulatory holds, or contamination could push commercial supplies to H2 FY28 or later. A ₹200–300 Cr revenue stream becomes ₹50–100 Cr for 2 years.
4
MediumCDMO customer concentration undisclosed; major program destocking or customer exit post-validation
100–125 customers but no granular breakdown given. Project value ranges from ₹1.5–75 M ($200K–$10M). If one customer (assumed <5% of ₹875 Cr = <₹45 Cr) exits or phases out post-dev, the 86% YoY growth rate is jeopardized.
5
MediumRaw material or amino acid supply-chain inflation erodes Affordable Medicines margins
ARV/FDF segment growing only 13% YoY; pricing power is limited in generics. A supply shock could compress OPM from 34% to 32–33%. Management hedges but has not disclosed hedging coverage.
6
Low–MediumValuation at ₹2,348 (RSI 71.8) is pricing in near-perfect CDMO execution; limited upside cushion
Stock is overbought and FII are trimming. If Q3 is soft or Q4 peptide batches disappoint, pullback to ₹1,900–2,100 is plausible (10–19% downside). Holders are betting on validation catalysts.
What to watch next (the resolution catalysts)
1 · Q3 FY27 print (expected "soft" — how soft?)
Management flagged Q3 as soft due to Laurus Bio validation and capacity commissioning. The street is braced for a dip. If Q3 revenue is >₹2,050 Cr (flat QoQ) and EBITDA margin holds >32%, the derisking narrative holds. If Q3 <₹1,950 Cr (-12% QoQ), it's a warning sign that Laurus Bio issues are deeper than campaign phasing.
2 · Peptide validation batch results (Q4 FY27–Q1 FY28)
Management committed to "validation 12–18 months" with "commercial scale batches" expected Q4 FY27 onward. These are binary: either the 16,000-liter SPPS reactor qualifies on schedule, or it doesn't. No batches shown by end-Q4 FY27 = material delay flag. Batches shown but at low yields = pricing risk.
3 · KRKA JV formulation facility validation kick-off (mid-2027)
KRKA (India formulation facility, 60% Laurus stake) is supposed to validate mid-2027 and contribute by FY28–29. A 12-month slip (validation delayed to mid-2028) would signal execution headwinds across all three major capex programs simultaneously — a red flag.
The single number to track
Forget reported PAT. Watch free cash flow for the next 8 quarters. If FCF turns negative or drops to <₹500 Cr annually (due to ₹3,000 Cr capex), the balance sheet enters a stress regime and the stock re-rates lower regardless of CDMO growth. The measure of whether capex is being deployed wisely is OCF minus capex, not revenue growth.
Laurus Labs has earned the right to be called a structural CDMO compounder: the Q2 print proves it. But the company has also just bet its balance sheet and two years of cash flow on peptide and Laurus Bio scaling on time. The capex raise is not a sign of confidence — it is a sign of capital intensity. The quarter is strong. The next two are the test. A 'Hold' at these valuations (RSI overbought, FII trimming) is appropriate until one of the three validation catalysts (Laurus Bio H2, peptide batches, KRKA mid-2027) confirms the capex bet is tracking. Upside to ₹2,700–2,800 if peptide validates on time and Laurus Bio ramps FY28. Downside to ₹1,800–1,900 if either slips by 12 months. The stock is fairly priced for on-time execution. It is expensive for delays.
Informational and educational content only. Not investment advice.